M. Wiesmann

发表

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Joshua M. Korn, Derek Y. Chiang, Tara L. Naylor, 2015, Nature Medicine.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

W. Sellers, D. Fabbro, Christopher J. Wilson, 2011, Molecular Cancer Therapeutics.

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

Yan Tang, Sang H. Lee, Yan Tang, 2005, Clinical Cancer Research.

Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.

M. Wiesmann, D. Bussiere, C. Shafer, 2006, Bioorganic & medicinal chemistry letters.

Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

M. Wiesmann, P. Manley, N. Brownlow, 2008, Leukemia.

Abstract 4497: NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models

W. Sellers, K. Shoemaker, C. Schnell, 2010 .

Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials

W. Sellers, K. Shoemaker, C. Schnell, 2010 .

Investigation of Correlation Among Safety Biomarkers in Serum, Histopathological Examination, and Toxicogenomics

F. Pognan, M. Wiesmann, J. Markovits, 2011, International journal of toxicology.

Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite

M. Wiesmann, M. Walles, P. Swart, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.

M. Wiesmann, C. Shafer, J. Jansen, 2006, Bioorganic & medicinal chemistry letters.

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

Simon Ng, Yanchen Zhang, Kenneth Crawford, 2011, ACS medicinal chemistry letters.

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.

Nikolaus Stiefl, J. Mestan, N. Stiefl, 2010, Bioorganic & medicinal chemistry.

Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.

K. Shoemaker, M. Wiesmann, W. Fantl, 2010, Bioorganic & medicinal chemistry letters.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.

Robert N. Taylor, M. Wiesmann, W. Fantl, 2003, Cancer research.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

J. Lehár, Manway Liu, R. Schlegel, 2014, Cancer cell.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

Eric Y. Durand, J. Lehár, W. Sellers, 2017, Proceedings of the National Academy of Sciences.

Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors

M. Wiesmann, W. Fantl, J. Escobedo, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

M. Wiesmann, J. Griffin, Irene Simkin, 2015, Molecular Cancer Therapeutics.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Hans Bitter, Joerg Kallen, Pascal Furet, 2015, eLife.

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Hong Chang, S. Trudel, M. Wiesmann, 2004, Blood.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.

Z. Ni, M. Wiesmann, C. Voliva, 2013, Bioorganic & medicinal chemistry letters.

Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.

Johanna M Jansen, M. Wiesmann, P. Feucht, 2009, Journal of medicinal chemistry.

A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues

A. Hierlemann, M. Rausch, M. Wiesmann, 2021, Frontiers in Pharmacology.

Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma

G. Caponigro, R. Schlegel, M. Wiesmann, 2014 .

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

W. Sellers, Philipp Holzer, P. Furet, 2015, eLife.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.